For someone diagnosed with cancer, the search for a clinical trial can feel like a second, isolating disease. The process is fragmented, often reliant on a physician’s limited bandwidth and manual searches across hundreds of registries. Leal Health, a New York-based startup formerly known as TrialJectory, is betting that an AI-powered platform can be a more humane and systematic guide. The company reports its algorithms have already facilitated more than three million treatment matches, connecting patients, clinicians, and pharmaceutical companies in a single workflow [leal.health, Unknown].
From Personal Experience to Platform
The company's origin is rooted in a founder's firsthand encounter with the system's gaps. CEO Tzvia Bader is a stage-IV melanoma survivor, and her personal cancer journey, alongside her mother's experience, directly motivated the launch of Leal Health [leal.health, January 2023]. This patient-centric perspective is embedded in the product's design, which asks users for self-reported clinical data, biomarkers, and treatment preferences to find relevant options [TechCrunch, December 2019]. The founding team blends this clinical empathy with technical depth. CTO and co-founder Guy Gildor brings over two decades of experience in complex data mining and algorithm development, including work for the Israeli military, while Chief Scientific Officer Avital Gaziel provides the necessary grounding in clinical research and medical affairs [Crunchbase, Unknown] [The Org, Unknown].
The AI-Powered Matching Engine
At its core, Leal Health operates as a decision-support layer for oncology. The platform analyzes a patient's profile against a vast database of available treatments and clinical trials, aiming to surface advanced options a treating oncologist might miss. The company has since expanded the platform to include FDA-approved cancer treatment decision support, creating what it calls a single point of access for patients [Fierce Biotech, Unknown]. For pharmaceutical and biotechnology companies, the platform serves as a recruitment and analytics tool, helping to identify and enroll appropriate trial participants while providing data on patient barriers and motivations [Business Insider, June 2023]. This dual-sided model,serving both patients and sponsors,is central to its commercial thesis.
Traction and Funding for Scale
Leal Health has attracted venture capital to build out this vision. The company has raised a total of $27.7 million across several rounds, according to its own reporting [Business Insider, July 2023]. A $20 million Series A in February 2022 was led by Insight Partners, with participation from Contour Venture Partners, JAL Ventures, RHO Ventures, and TIA Ventures [Startup Intros, Unknown]. This capital has fueled growth. In 2021, the company reported it was on track to match 50,000 cancer patients with clinical trials that year, with 35% of those matched coming from underrepresented groups [TechCrunch, November 2021].
| Round | Amount (USD) | Lead Investor | Key Participants | Date |
|---|---|---|---|---|
| Seed | $2.7 million | BOB Greene | Not specified | December 2019 [Startup Intros, Unknown] |
| Series A | $20 million | Insight Partners | Contour Venture Partners, JAL Ventures, RHO Ventures, TIA Ventures | February 2022 [Startup Intros, Unknown] |
| Total Reported Funding | $27.7 million | July 2023 [Business Insider, July 2023] |
Navigating a Complex Clinical Landscape
The ambition is clear, but the path is lined with the inherent complexities of healthcare. The platform's effectiveness hinges on the quality and comprehensiveness of its underlying data. While it uses self-reported patient information, the integration with electronic health records (EHRs) or real-time clinical data feeds is not detailed in public materials, leaving questions about how the system stays current with a patient's evolving status. Furthermore, the regulatory environment for clinical decision support software is evolving. The company notes its platform includes FDA-approved treatment support, but the full scope of that clearance and how it navigates the distinction between providing information and making a medical recommendation is a nuanced challenge [Fierce Biotech, Unknown].
The competitive landscape, while not named in sources, is also formidable. The clinical trial matching space includes large patient advocacy networks, dedicated CRO (contract research organization) software, and hospital-based internal tools. Leal Health's answer appears to be a focus on patient experience and its generative AI features, which are intended to assist both patients and staff in navigating complex information [Techstrong.ai, March 2024]. Its early traction in reaching underrepresented populations could become a significant differentiator for trial sponsors increasingly focused on diversity.
The Standard of Care and the Road Ahead
For the millions of patients navigating an oncology diagnosis each year, the current standard of care for finding a trial is often a frustrating patchwork. It typically depends on an oncologist's own network and manually searching clinicaltrials.gov, a process that is time-consuming and can easily miss relevant options based on specific biomarkers or genetic markers. Patients who attempt to self-advocate are faced with a labyrinth of medical jargon and disparate information sources. Leal Health is attempting to build a bridge over this gap, offering a centralized, AI-filtered view of the landscape.
The next twelve months will be critical for the company to demonstrate it can convert its reported millions of matches into a sustainable, scaled business. Key milestones to watch include the announcement of named pharmaceutical partners, deeper integrations with major healthcare provider networks, and further validation of its match outcomes through peer-reviewed studies. For patients with advanced solid tumors or rare cancers where standard therapies have been exhausted, the promise of a platform like Leal's is not merely convenience, but hope. The company's continued progress will be measured not just in funding rounds or match counts, but in how many of those matches lead to a patient enrolling in a trial that could extend or save their life.
Sources
- [leal.health, Unknown] Leal Health homepage | https://leal.health/
- [leal.health, January 2023] Leal Health, Our Story | https://leal.health/post/our-story
- [TechCrunch, December 2019] Trialjectory uses self-reported clinical data to match cancer patients with clinical trials | https://techcrunch.com/2019/12/17/trialjectory-uses-self-reported-clinical-data-to-match-cancer-patients-with-clinical-trials/
- [Crunchbase, Unknown] Leal Health - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/trialjectory
- [The Org, Unknown] Avital Gaziel profile | https://theorg.com/org/leal-health/org-chart/avital-gaziel
- [Fierce Biotech, Unknown] Leal Health expands platform | https://www.fiercebiotech.com/medtech/leal-health-expands-ai-platform-include-fda-approved-cancer-treatment-decision-support
- [Business Insider, June 2023] VCs Name the Most Promising Healthtech Startups in 2023 | https://www.businessinsider.com/vcs-most-promising-startups-healthtech-2023-6
- [Business Insider, July 2023] VCs Name the Most Promising Healthtech Startups in 2023 | https://www.businessinsider.com/vcs-most-promising-startups-healthtech-2023-6
- [Startup Intros, Unknown] Leal Health funding details | https://startupintros.com/orgs/leal-health
- [TechCrunch, November 2021] Trialjectory on track to match 50K cancer patients with clinical trials this year | https://techcrunch.com/2021/11/12/trialjectory-on-track-to-match-50k-cancer-patients-with-clinical-trials-this-year-35-are-from-underrepresented-groups/
- [Techstrong.ai, March 2024] AI Leadership Insights: AI for Health Platform | https://techstrong.ai/videos/ai-leadership-insights-ai-for-health-platform/